The KCNJ2 Knockout AGS Polyclonal Cells consist of a CRISPR/Cas9-edited heterogeneous population of AGS human gastric adenocarcinoma epithelial cells carrying a targeted disruption of the KCNJ2 gene. This polyclonal knockout product provides a versatile loss-of-function model for studying inward rectifier potassium channel Kir2.1 function in gastric epithelium, as it abolishes endogenous KCNJ2 expression across a mixed genetic background without clonal selection. The cell pool is designed to facilitate investigation of ion channel-dependent processes in a cancer-relevant context, enabling robust functional assays while mitigating clone-specific artifacts.
AGS is a widely characterized human gastric adenocarcinoma cell line derived from a female patient, serving as a standard in vitro model for gastric carcinogenesis, H. pylori infection studies, and anticancer drug response evaluation. These adherent epithelial cells retain key features of gastric mucosa, including expression of mucins, growth factor receptors, and polarity markers, making them suitable for investigating tumor cell signaling and pharmacological interventions. The genetic background of AGS encompasses common mutations found in gastric cancer, providing a disease-relevant platform for gene perturbation studies.
KCNJ2 encodes the inward rectifier potassium channel Kir2.1, which maintains the resting membrane potential through constitutive potassium efflux and is regulated by extracellular potassium, membrane depolarization, intracellular pH, and phosphorylation by PKA and PKC. Kir2.1 interacts with scaffolding proteins SAP97 and MAGI-1, and associates with ??-catenin (CTNNB1) and E-cadherin at cell junctions, coupling ion flux to adhesion and signaling. The channel functions upstream of PI3K (PIK3CA)/Akt (AKT1) and MAPK/ERK (MAPK3/1) pathways, promoting cyclin D1 (CCND1) expression and inhibiting p21 and pro-apoptotic factors Bcl-2 and Bax. Loss of KCNJ2 disrupts the inward rectifier potassium current (IK1), depolarizes the membrane, and attenuates Akt1 and ERK1/2 phosphorylation, thereby destabilizing ??-catenin and altering cell cycle and survival regulators.
In AGS gastric cancer cells, endogenous Kir2.1 activity has been implicated in proliferation, migration, and apoptosis resistance, partly through sustaining PI3K/Akt and Wnt/??-catenin signaling. CRISPR/Cas9-mediated ablation of KCNJ2 is expected to depolarize the membrane and abrogate the potassium conductance required for cell cycle progression and volume regulation, impairing cyclin D1 expression and relieving inhibition of pro-apoptotic factors. Consequently, this knockout model enables dissection of potassium channel contributions to gastric adenocarcinoma pathology, with relevance also to Andersen-Tawil syndrome, colorectal cancer, atrial fibrillation, and short QT syndrome, where KCNJ2 mutations play pathogenic roles.
Researchers can employ these polyclonal knockout cells in functional electrophysiology studies using patch-clamp recordings to verify IK1 current ablation, complemented by Western blotting for Kir2.1 protein and RT-qPCR for KCNJ2 transcript validation. The population is well-suited for cell-based assays measuring proliferation (MTT or colony formation), apoptosis (Annexin V), and migration (Transwell), enabling systematic dissection of potassium channel?Cdependent oncogenic mechanisms. This model also supports pharmacological screening for Kir2.1 channel modulators and genetic rescue experiments, offering a tractable system for gastric cancer biology, ion channel drug discovery, and disease modeling. For further technical details, storage recommendations, or ordering information, please contact Ascent Research.
